By Karen Roman
Kineticos Life Sciences said it has partnered with Orthobond, a biotechnology company focused on medical devices, through investment from the Kineticos AMR Accelerator Fund I.
Kineticos strategic advisor Steve Favaloro will be joining Orthobond’s Board of Directors, it said in a statement.
The financing will contribute to gain FDA approval for new technologies like Orthobond previously did with Ostaguard, its anti-bacterial non-drug eluting solution for spine implants, it stated.
“The KAMRA Fund I was established to support pioneers who are addressing antimicrobial resistance and we are delighted to partner with the Orthobond team, who have demonstrated persistence and commitment to making an impact for patients by reducing bacterial contamination during implant surgery,” said Mark Bamforth, member of the KARMA Fund I General Partnership.
Contact:
